Mink Therapeutics Inc

$11.68 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Mink Therapeutics Inc

MiNK Therapeutics, Inc. is a biopharmaceutical company. The Company is specialized in discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD). The Company offers platform, which is designed for reproducible manufacturing for off-the-shelf delivery. Its product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is in multiple Phase I clinical trials, which is used for the treatment of multiple myeloma.

Stock Analysis

last close $11.6
1-mo return -35.2%
3-mo return -
avg daily vol. 59.53T
52-week high 22.16
52-week low 11.2
market cap. $652M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $--
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe